Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3B. The listing ...

Shares of weight-loss drug developer Metsera surged nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture Partners-backed biotech firm at $2.68 billion. Shares of the company opened ...

The Company has added an Australian entity, Max Brazil, to hold the "Florália DSO Project" through the existing Canadian and Brazilian holding entities. As announced on January 9, 2025, Max Brazil ...

Metsera, along with Maze Therapeutics, gave U.S. health care first-time share sales its best month since October.

Sources privy to the development said that the company is actively streamlining its operations to address various challenges ...

The UK biotech sector raised £3.5 billion in equity financing last year amid challenges, according to a BIA report.

The company launched the IPO after doubling revenue in 2024, driven by increased oil production from well acquisitions worth ...

BloombergNEF says in a new report that global clean energy investment reached $2.1 trillion in 2024, more than doubling 2020 ...

Infinity is going public after more than doubling its revenue in the first nine months of 2024. The strong growth came as the ...

Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...